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ABSTRACT 
 
Background 
The sensitivity and specificity of the subcutaneous implantable cardioverter 
defibrillator (S-ICD) pre-implant screening tool required clinical evaluation. 
Methods 
Bipolar vectors were derived from electrodes positioned at locations similar to those 
employed for S-ICD sensing and pre-implant screening electrodes, and recordings 
collected through 80-electrode PRIME
®
-ECGs, in six different postures, from 40 
subjects (10 healthy controls, and 30 patients with complex congenital heart disease 
(CCHD); 10 with Tetralogy of Fallot (TOF), 10 with single ventricle physiology 
(SVP), and 10 with transposition of great arteries (TGA). The resulting vectors were 
analysed using the S-ICD pre-implant screening tool (Boston Scientific) and 
processed through the sensing algorithm of S-ICD (Boston Scientific). The data were 
then evaluated using 2x2 contingency tables. Fisher exact and McNemar tests were 
used for a comparison of the different categories of CCHD, and <0.05 vs. controls 
considered to be statistically significant. 
Results 
57% of patients were male, mean age 36.3 years. The sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) of the S-ICD screening 
tool were 95%, 79%, 59% and 98%, respectively, for controls, and 84%, 79%, 76% 
and 86%, respectively, in patients with CCHD (=0.0001).  
Conclusion 
The S-ICD screening tool was comparatively more sensitive in normal controls but 
less specific in both CCHD patients and controls; a possible explanation for the 
reported high incidence of inappropriate S-ICD shocks. Thus, we propose a pre-
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implant screening device using the S-ICD sensing algorithm to minimise false 
exclusion and selection, and hence minimise potentially inappropriate shocks.   
 
 
Keywords: Sudden Cardiac death, congenital heart disease, subcutaneous 
implantable Cardioverter, sensing algorithm. 
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INTRODUCTION 
Implantable cardioverter defibrillators (ICD) are considered to be the most effective 
treatment for primary and secondary prevention of sudden cardiac death (SCD) [1-5].  
The main function of ICD is to sense and terminate potentially fatal ventricular 
arrhythmias. However, the conventional transvenous ICDs carry risks of a variety of 
complications [6-8]. These complications include procedural (bleeding, 
pneumothorax, vascular damage and myocardial perforation), short-term (infection, 
thrombosis) and long-term (lead failure, inappropriate shocks) factors [8].  
The use of transvenous ICD is conservative in patients with congenital heart diseases 
(CHD) because of the anatomical challenges and higher risk of life long 
complications; despite the fact that these people experience a high rate of SCD at 
young age and would benefit most from ICD [9, 10]. The totally subcutaneous 
implantable cardioverter defibrillator (S-ICD) has been developed, and used in a 
selected number of patients because of the limitations of transvenous ICD. S-ICDs are 
entirely subcutaneous, and aim to reduce complications through avoidance of the use 
of intracardiac leads [11-13]. However, despite these advantages, the S-ICD is limited 
by inability to provide anti-tachy pacing (ATP) and can provide post shock brady 
pacing for 30 seconds only [11]. Additionally, selection for S-ICD implant is based on 
pre-implant electrographic body surface mapping [14].  
The S-ICD consists of a pulse generator (SQ-RX® pulse generator Boston Scientific) 
[14], implanted subcutaneously in the left mid-axillary line at the level of the fifth and 
sixth intercostal spaces [14]. The L-shaped S-ICD lead (Q-TRAK® lead, Boston 
Scientific) is inserted subcutaneously and has two segments, (i) a horizontal segment 
which is attached to the S-ICD pulse generator and continues as a (ii) a vertical 
segment parallel to the left sternum edge [14]. This configuration offers three sensing 
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vectors (Figure 1) [11, 15]. Pre-implant screening identifies the most appropriate 
sensing vector, which is then confirmed by post implant device interrogation. 
However, the current generation of S-ICD do not automatically select the sensing 
vector. The S-ICD uses subcutaneous electrocardiogram (ECG) signals to monitor 
cardiac output and discriminate between shockable and non-shockable rhythms [15].  
Early trials of S-ICD defibrillation ability have demonstrated effective termination of 
VT and VF similar to transvenous ICDs [11, 15]. However, recent clinical studies 
have reported inappropriate shocks in at least 7-13% cases within one year of implant 
suggesting that the sensing algorithm requires further evaluation [11, 12, 15-21].  
Bellardine et al. have demonstrated a good correlation between subcutaneous and the 
corresponding transcutaneous body surface ECGs [22], suggesting that it is feasible to 
study the sensing algorithm of S-ICD through surface ECG measurements. 
Additionally, patient selection for S-ICD implant is based on pre-implant screening; 
carried out using a three-lead surface ECG, acquired in both supine and standing 
postures. The ECG tracings are then mapped out using the Boston Scientific screening 
tool; intended to identify patients with acceptable sensing characteristics [14, 15]. 
However the diagnostic and discriminatory ability (sensitivity and specificity) of the 
pre-implant screening tool against the sensing algorithm of S-ICD is not known. 
In this study we have tested the sensitivity and specificity of the pre-implant screening 
tool against the sensing algorithm of the S-ICD in six postures (standing, sitting, 
supine, left lateral, right lateral, prone) for three vectors. Four subgroups were 
considered; including normal adults and adults with complex congenital heart 
diseases (Tetralogy of Fallot (TOF), transposition of great arteries (TGA) and single 
ventricle physiology (SVP). 
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METHOD 
This observational study was conducted at the tertiary care cardiology centre of our 
university teaching hospital. Patients were identified from their records upon 
presentation to the inpatient and outpatient departments and anonymised by 
assignment of a unique ID number.  
This study received approval from an independent review board of the Southampton 
University Hospital & South West Hampshire Research Ethics Committee B (REC 
08/H0504/55).  
 
Study Population 
All the subjects were aged 18 years or over and had the ability to give informed 
consent. 
Forty patients were recruited into the following subgroups. 
1. Ten adults with morphologically normal heart on cardiac magnetic resonance 
imaging (half of these patients had assessment with late gadolinium enhancement at 
the discretion of the attending radiologist and showed no abnormality). 
2. Ten adults with TOF. 
3. Ten adults with TGA. 
4. Ten adults with SVP. 
Patients in arrhythmias and paced rhythm were excluded from the study. 
 
Electrocardiographic Data collection 
Electrocardiographic body surface mapping was performed through 80-electrode 
ECG (PRIME
®
-ECG Verathon Inc); consisting of an on-board computer and flexible 
plastic anterior and posterior electrode vests, as described previously [23, 24]. The 
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anterior vest contains 64 electrodes and the posterior vest contains 16 electrodes, thus 
enabling the recording of 80 simultaneous ECG signals [23, 24]. The vests are 
arranged in vertical strips referenced to their anatomical landmarks. In each subject, 
80-electrode ECGs were recorded in six postures (standing, sitting, supine, left lateral, 
right lateral, prone), for 10 seconds, at a sweep speed of 25 mm/s, and a sampling rate 
of 1kHz. Adequate adhesion of individual ECG skin electrodes and good quality 
signal collection were ensured through prior skin preparation, shaving hair where 
necessary and using alcohol wipes. Three bipolar vectors were created from 
electrodes at locations mimicking the placement of the S-ICD sensing electrodes as 
recommended by the manufacturers (Boston Scientific) for pre-implant screening 
(Figure 1) [14]. The bipolar vectors Lead I, Lead II and Lead III were derived, 
representing surface ECG equivalent of Boston Scientific sense vectors (Primary = 
Lead III, Secondary = Lead II, Alternate = Lead I). Each vector was created at gain 5, 
10, 15 and 20 mm/mV.  
 
Screening tool and bipolar vectors analysis 
The manufacturer of the currently available S-ICD (Boston Scientific) recommends 
pre-implant screening through surface ECG in all patients considered for S-ICD.  A 
pre-implant screening tool is used to identify patients with acceptable sensing 
characteristics, prior to the implant of S-ICD. This is a printed chart, containing six 
profiles of varying morphology, with a horizontal line passing through all the colour 
profiles to adjust with the baseline. Each colour profile has an identical window above 
and below the baseline; to account for positive or negative amplitude of the R-wave 
and T-wave. Each window is subdivided by dotted lines and the peak of the R-wave 
has to lie within this sub-window for of one of the six profiles to be appropriate for 
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sensing. Additionally, the trailing T-wave has to be contained within the same colour 
profile as the R-wave for the vector to be appropriate for sensing (Figure 2) [14]. This 
screening tool was used to evaluate each vector. A coloured map from the screening 
tool that best matched the amplitude and duration of the QRS complex and the T-
wave was determined. For biphasic signals, the larger peak was used. The left-hand 
edge of the selected coloured map was aligned with the onset of the QRS complex. 
The horizontal line on the coloured template was used as a guide for isoelectric 
baseline alignment. The QRS peak had to be within the window bounded by the 
dotted line and the peak of the coloured profile (Figure 2). If, when printed at the 
maximum 20mm/mV gain, the QRS peak did not reach the minimum boundary 
(dotted line) of the smallest coloured profile, the vector was considered unacceptable. 
If the entire QRS complex and trailing T-wave were contained within the coloured 
profile, the vector/posture combination was considered suitable. If any portion of the 
QRS complex or trailing T-wave extended outside the coloured profile, the sense 
vector was considered unacceptable. All vectors were examined individually at four 
gain settings (5, 10, 15 and 20 mm/mV); mimicking the automatic gain adjustment of 
the sensing algorithm. A vector acceptable at any of these gains was considered 
suitable. 
 
Analysis of the bipolar vectors by S-ICD sensing algorithm 
The data from the three bipolar vectors was exported in Matlab® readable format. 
The three bipolar vectors were then presented to the S-ICD sensing algorithm (built in 
Matlab® by Boston Scientific) and this algorithm identified the vectors suitable or 
unsuitable for rhythm discrimination, based on the current sensing algorithm of the S-
ICD. The sensing algorithm has an automatic gain adjustment function, therefore no 
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external manipulation of gain for the vectors is required before assessment using the 
sensing algorithm. 
 
Statistical analysis 
Statistical analyses were performed using the SPSS 19.0 software package (IBM 
SPSS limited). Continuous variables were expressed as mean ±1 SD and were 
compared using Student’s t test. Sensitivity and specificity were determined using 2x2 
contingency tables and comparison of dichotomous categorical variables was made by 
x
2
 test.  Fisher’s exact test and McNemar chi square test were used to determined 
significant differences between different groups on the basis of cardiac morphology, 
lead position and postures. A < 0.05 was considered significant.  
 
RESULTS 
A total of 2880 vectors collected from 40 subjects (10 normal control and 30 complex 
congenital heart disease (CCHD) patients (10 Tetralogy of Fallot (TOF), 10 single 
ventricle physiology (SVP), 10 transposition of great arteries (TGA)) were generated 
and analysed in groups of three bipolar vectors for each of the 6 postures, at gain 5, 
10, 15 and 20 mm/mV from 240 BSM (80-electrode PRIME
®
-ECGs). The mean age 
was 36.3±14.4, and 57% (23/40) were male.  
 
Table 1 summarises the results of screening tool sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), positive likelihood ratio 
(+LR), negative likelihood ratio (-LR) and 95% confidence interval (95% CI) for all 
subjects, normal controls, CCHD patients (TOF, TGA, SVP), three vectors (Lead III, 
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Lead II, Lead I) and six postures (standing, sitting, supine, left lateral, right lateral, 
prone). 
 
The screening tool displayed high sensitivity and lower specificity in normal controls. 
The sensitivity and specificity of the screening tool were significantly lower in 
individuals with CCHD compared with individuals with normal heart morphology 
(<0.05) (all CCHD =0.001, TOF =0.001, TGA =0.001, SVP =0.001), and in 
Lead III in comparison to primary Lead I (=0.004). However, there was no 
significant difference in Lead II compared with Lead III or in the six postures 
compared with supine (all >0.05).   
 
DISCUSSION 
The sensing algorithm of the S-ICD depends on the surface (subcutaneous) ECG 
morphology, specifically the R-wave amplitude, T-wave amplitude, R/T ratio, QRS 
duration and QT interval.  A pre-implant screening tool has been developed by the 
manufacturers (Boston Scientific) taking into account these ECG parameters [14]. 
The screening tool is used in all patients under consideration for S-ICD implantation; 
to select individuals with ECG morphology that offering appropriate signal 
configuration to satisfy the requirements of the S-ICD sensing algorithm critical for 
appropriate delivery of ICD therapy [14] . In this study the performance of the 
screening tool was compared against a gold standard (sensing algorithm prepared by 
the manufacturers (Boston Scientific) in Matlab
®
.  
Our study demonstrated sensitivity and specificity of the S-ICD pre-implant screening 
tool in individuals with normal cardiac morphologies that is compatible with patient 
selection for subcutaneous ICD therapy and an expectation of delivery of appropriate 
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therapy. However, the sensitivity and specificity of the screening tool were 
significantly lower in individuals with CHD (p=0.001) compared with normal 
controls. The screening tool was developed using data from adults with normal 
cardiac morphologies, accounting for the higher sensitivity in this group. The 
sensitivity and specificity of the screening tool was highest in Lead I, followed by 
Lead III; there was no statistically significant difference between Lead II and Lead 
III. There were no statistically significant differences in sensitivity and specificity of 
the screening tool between the six postures.  
This study showed a high sensitivity but relatively lower specificity of the S-ICD 
screening tool across all the groups, leads and postures. In clinical terms, most 
suitable patients for S-ICD implantation (true positives) are identified by the 
screening tool but there are many false positives (unsuitable patients, likely to have 
poor performance of the detection algorithm due to subcutaneous ECG features). In 
this study, the screening tool had a high probability of selecting individuals 
inappropriate for S-ICD. 
The current criteria of patient selection for S-ICD is less well defined and the 
clinicians are left with the dilemma that whether to accept a patient with just one 
suitable vector, or multiple suitable vectors for S-ICD implant. It is possible that more 
than one suitable vectors would enable more stable sensing configurations; however, 
the current generation of S-ICD is limited in its ability of automatic mode switching 
between sensing vectors, and requires the use of device programmer for manual 
reconfiguration, thus in current settings the suitability of multiple vectors have limited 
role. 
There are limited published data regarding the performance of the pre-implantation 
screening tool; especially in patients with structural abnormality due to congenital 
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heart disease. However, for appropriate S-ICD sensing, it is vital to identify suitable 
candidates. The START study directly compared transvenous and subcutaneous devices, 
by assessing their respective abilities to discriminate between arrhythmias [15]. This 
study showed that all ICDs tested had >99 % appropriate detection for ventricular 
tachyarrhythmias, but the specificity of supraventricular arrhythmias discrimination 
was markedly higher for S-ICDs (98%) than for two of three transvenous devices tested 
(76.7% and 68%) [15]. Similarly, further clinical studies demonstrated the excellent 
ability of the S-ICD for rhythm discrimination [16, 17, 19, 25]. However, most of these 
studies on the rhythm discrimination were performed immediately after implantation of 
S-ICD with patients in a supine posture and this poses questions regarding “real life” 
performance of S-ICD sensing. Additionally, recent clinical studies have reported 
inappropriate therapies in as many as 13% of therapy deliveries at one-year follow-up 
in patients having had S-ICD implantation [12, 20, 26]. In the majority of these cases, the 
inappropriate therapies were due to sensing algorithm failure rather than mechanical 
factors, such as subcutaneous lead displacement [20]. The recently published 
EFFORTLESS S-ICD registry of 472 patients with follow-up at 558 days, reported a 360-
day inappropriate shock rate of 7% with the vast majority occurring due to T-wave 
oversensing of cardiac signals [27]. We speculate that the relatively low specificity of the 
screening tool may have allowed patients with ECGs that were not appropriate for the S-
ICD to have received the device; resulting in inappropriate sensing and therapies. 
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We suggest that the sensitivity and specificity of the screening method can be 
improved by using a device with a “live virtual” sensing algorithm for the pre-implant 
screening purpose. This device would allow testing of the potential sense vector by a 
fully-featured sensing algorithm in all patients considered for S-ICD implantation and 
specificity of selection should be improved. 
 
LIMITATIONS 
Our study has several limitations. Firstly, the sample sizes are small, due to limited 
resources, time constraints, and the relative difficulty of finding appropriate patients, 
having the relevant structural cardiac defects, for inclusion in the four categories. 
However, all data were collected by a single investigator to reduce variation, and 
furthermore, the sample size for the current study was selected to mimic preclinical 
drug safety studies [28]. Secondly, since ECGs were collected from individuals in 
sinus rhythm at rest, there is the possibility of variation in the morphologies of ECGs 
during exercise and arrhythmia. However, in this study the Boston Scientific S-ICD 
pre-implant screening method was followed and this method recommends collection 
and analysis of resting surface ECGs. More recently, screening is also performed on 
ECGs acquired during exercise [14]. Considering the patient population who are 
likely to receive an ICD, the congenital heart disease cohort sampled was limited to 
three groups – Tetralogy of Fallot, transposition of the great arteries and single 
ventricle physiology. However, these conditions represent the most complex 
congenital structural abnormalities [29]. Although such defects are rare, they do 
represent patients who have a high burden of ventricular arrhythmias and the risk of 
sudden death [29]. Also, the number of complex CCHD patients attached to any 
single centre is small and therefore difficult to recruit. Compounding factors were 
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reduced by recruiting 10 near age and sex matched subjects from normal control, 
TOF, TGA and SVP patients. 
 
CONCLUSION 
The screening tool plays a vital role in the selection of appropriate candidates for S-
ICD implantation. In this study the screening tool itself proved to be highly sensitive 
in identifying S-ICD patients without CHD and would satisfy the requirements of the 
detection algorithms but it was too non-specific in that it also selected patients who 
would not. Additionally, the screening tool is significantly less sensitive in patients 
with CHD. We propose the use of a device with a real-time sensing algorithm for 
screening purposes, that would allow testing of the potential sense vector through that 
algorithm in patients considered for S-ICD and so permit a more rigorous assessment 
of patient suitability; with the aim of reducing inappropriate shock therapies. 
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Figure 1 
 
 
Figure 1: S-ICD generator and lead position. This figure shows the position of 
subcutaneous sensing arrays and location of bipolar three lead ECG leads placement 
to generate Lead I, Lead II and Lead III for S-ICD pre-implant screening. [ECG= 
Electrocardiology, S-ICD= subcutaneous implantable cardioverter defibrillator] 
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Figure 2 
 
 
Figure 2: Pre-implant (Boston Scientific) screening tool to identify patients with 
acceptable sensing characteristics prior to the implant of S-ICD. If the entire QRS 
complex and trailing T-wave is contained within the coloured profile, the 
vector/posture combination is deemed acceptable. If any portion of the QRS complex 
or trailing T-wave extends outside of the coloured profile, the sense vector is deemed 
unacceptable. 
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Table 1: Subcutaneous ICD screening tool sensitivity, specificity, positive predictive 
value, negative predictive value, positive likelihood ratio, negative likelihood ratio, 
Fisher exact and McNemar p value for comparison of different categories. [95% CI= 
95% confidence interval, TOF=tetralogy of Fallot, TGA=transposition of great 
arteries, SVP=single ventricle physiology]. 
 
 Sensitivi
ty %  
(95% CI 
%) 
Specific
ity %  
(95% 
CI) 
Positive 
predictive 
 value % 
(95% CI) 
Negative 
predictive  
value % 
(95% CI) 
Positive 
likelihood  
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
 p 
valu
e 
All 86 (81, 
90) 
79 (74, 
82) 
73 (68, 77) 89 (86, 92) 4 (3, 5) 0.2 (0.1, 
0.2) 
 
Norma
l  
95 (83, 
99) 
79 (70, 
85) 
59 (47, 70) 98 (93, 99) 4 (4, 6) 0.06 (0.01, 
2) 
 
C-CHD 84 (79, 
89) 
79 (74, 
83) 
76 (71, 81) 86 (81, 90) 4 (3, 5) 0.2 (0.1, 
0.2) 
0.00
1
 
TOF 77 (64, 
87) 
76 (68, 
83) 
60 (48, 71) 88 (80, 93) 3 (2, 4) 0.3 (0.2, 
0.5) 
0.00
1 
TGA 83 (73, 
90) 
76 (66, 
84) 
75 (65, 83) 84 (74, 91) 3 (2, 5) 0.2 (0.1, 
0.3) 
0.00
1
 
SVP 90 (82, 
95) 
86 (76, 
93) 
89 (81, 94) 87 (77, 93) 6 (4, 11) 0.1 (0.06, 
0.2) 
0.00
1
 
Lead 
III 
88 (80, 
93) 
72 (63, 
80) 
79 (72, 85) 83 (74, 90) 3 (2, 4) 0.2 (0.1, 
0.3) 
 
Lead II 83 (73, 
90) 
78 (72, 
85) 
68 (58, 77) 90 (83, 94) 4 (3, 6) 0.2 (0.3, 
0.6) 
1† 
Lead I 89 (78, 
95) 
83 (76, 
88) 
68 (58, 77) 94 (89, 97) 5 (4, 7) 0.1 (0.07, 
0.3) 
0.00
4†† 
Supine 79 (64, 
89) 
83 (72, 
89) 
76 (61, 86) 86 (75, 92) 5 (2, 8) 0.2 (0.1, 
0.4) 
 
Standi
ng 
86 (73, 
94) 
84 (73, 
91) 
80 (67, 89) 89 (78, 95) 5 (3,9) 0.2 (0.1, 
0.3) 
0.1§ 
Sitting 85 (71, 
93) 
80 (69, 
89) 
74 (60, 85) 89 (79, 95) 4 (3, 7) 0.2 (0.1, 
0.4) 
1§ 
Left 
lateral 
92 (79, 
97)  
73 (61, 
83) 
70 (57, 80) 93 (82, 98) 3 (2, 5) 0.1 (0.04, 
0.3) 
1§ 
Right 
lateral 
88 (74, 
96) 
71 (60, 
80) 
63 (50, 75) 92 (80, 97) 3 (2, 4) 0.2 (0.1, 
0.4) 
0.6§ 
Prone 89 (76, 
96) 
82 (71, 
90) 
76 (62, 96) 92 (82, 97) 5 (3, 8) 0.1 (0.05, 
0.3) 
0.1§ 
Fisher exact p value derived in comparison to individual with normal heart morphology. 
†McNemar p value derived in comparison to primary vector (Lead III). 
§McNemar p value derived in comparison to supine posture. 
